Proactive Investors - Run By Investors For Investors

Imugene Ltd to start gastric cancer treatment studies in Taiwan

Imugene Ltd to start gastric cancer treatment studies in Taiwan

Imugene Ltd (ASX:IMU) has received approval from the Institutional Review Board of the Taipei Veterans General Hospital in Taiwan for the Phase 1b/2 study of its HER-Vaxx immuno-oncology therapy in gastric cancer.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Rather than attacking the cancer directly, as chemo does, immunotherapy tries to rally the patient’s own immune system to fight the disease.

The approval in Taiwan follows the University of Hong Kong Institutional Review Board Approval in July.

Hong Kong and Taiwan are two of the eight study sites participating in the initial Phase 1b portion of the upcoming Phase 1b/2 study.

The initial Phase 1b will enrol up to 18 patients to be treated with HER-Vaxx in combination with chemotherapy to interrogate three dose levels.

This first stage is to obtain safety, immunogenicity (a measure of how many of the HER-2 antibodies are produced), evaluate the booster schedule and determine the optimal dose to take into the Phase 2 study.

The larger, open label Phase 2 study will enrol around 68 patients randomised into two arms of either HER-Vaxx plus standard-of-care or standard-of-care alone.

Gastric cancer represents an area of high unmet medical need, particularly in Asia.

Imugene held $1.6 million in cash as at 30 June 2016.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

man with erectile dysfunction
Mon
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use